Event Information

---

Cooley Life Sciences Practice Leader Barbara Kosacz will be leading a panel discussion on Outlicensing Trends.

---

Will wonders never cease? The simple fact is that big pharma, for a variety of reasons is now a big player in the formerly niche business of outlicensing. Previously a dirty word in pharma business development functions, outlicensing suddenly taken on a luster of precious metal. But are these opportunities 18 carat or fool's gold? Why the sudden change in value perceptions inside and outside pharma? Top strategists and thought leaders behind some of the biggest deals will share the rationale for their prolific outlicensing activities. If you're not in the game . . . find out what you're missing!

OBJECTIVES

• Explore the fastest growing segment of licensing and business development, transforming large and small company portfolios with the stroke of the pen.
• Learn how deal makers choose their partners and what criteria are used in making decisions.
• Discover how to position your small company as capable of taking on the challenges of clinical development of a later stage asset.
  
  

PANEL

Barbara Kosacz, Partner, Life Sciences, Cooley LLP
Barbara Yanni, VP & Chief Licensing Officer, Merck & Co, Inc
Martin Birkhofer, Vice President, Bristol-Myers Squibb Company
Shaun Grady, VP, Global Head of Transactions, AstraZeneca, Research & Development, Inc

For more information, please visit the event website.